科兴制药: 关于开立募集资金专项账户并签订募集资金专户存储三方监管协议的公告

Fundraising Overview - The company has successfully completed its initial public offering (IPO) of 49.6753 million shares at a price of RMB 22.33 per share, raising a total of RMB 1,109,249,449, with a net amount of RMB 994,640,919 after deducting issuance costs [1][2] Fund Management and Regulatory Compliance - The company has established a special account for the management of the raised funds and signed a tripartite supervision agreement with the sponsor and the bank where the funds are deposited [2][3] - The agreement aims to ensure the proper use of funds for the "R&D Center Upgrade Project" and prohibits the use of these funds for any other purposes [3][4] Account Opening and Agreement Details - A new fundraising special account has been opened at China Postal Savings Bank, and the agreement includes provisions for the management and supervision of the funds [3][4] - The agreement specifies that the company can store part of the funds in deposits but cannot directly withdraw from these deposits [4][5] Supervision and Reporting - The sponsor is responsible for ongoing supervision of the fund management, including conducting at least biannual inspections of the fund's storage and usage [4][5] - The company must notify the sponsor of any significant expenditures from the special account and provide necessary documentation [5]